Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,274.20569.4
Stock Analysis, IPO, Mutual Funds, Bonds & More
Strides Pharma board approves addnl USD 40 mn investment in Stelis Biopharma

The company's board has approved an additional investment up to a maximum of USD 40 million over a period of 24 months for a controlling stake in Stelis, Strides Pharma Science said in a statement.

Inspection of Unichem's Kolhapur facility by USFDA completed without observations

The inspection was a CGMP surveillance and pre-approval inspection and was successfully concluded without any FDA Form 483 issued.

Indian pharma exports to touch $22 billion this fiscal, Q1 exports stand at $5 billion

In July 2019, Indian exports recorded 21.7 per cent growth to 1.72 billion (total exports from April to July this year was at USD 6.17 billion), he said.

UK regulator reinstates full GMP status of Indoco Remedies Goa facility

With this development, the company's operations in Europe will now take off on a fast-track, Indoco Remedies MD Aditi Panandikar said.

Strides Pharma buys 70% in Swiss company

The acquisition further strengthens Strides' footprint in continental Europe.

Sun Pharma arm acquires remaining 3.04 pc stake in PJSC Biosintez

The company's subsidiary - Sun Pharma (Netherlands) BV - already had 96.96 per cent stake in pharma firm PJSC Biosintez prior to the purchase of these shares.

Lupin signs second partnership for its oncology pipeline, this time with German drug maker BI

BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer.

Sterling Biotech case: Far-reaching NCLAT order sets new bankrupcty precedent

The company's promoters, Chetan Sandesara and Nitin Sandesara, are absconding and believed to be in Africa.

Novartis's Sandoz licenses proposed multiple sclerosis biosimilar

The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Oxxy Healthcare to offer up to Rs 1,000 crore loan for medical treatment in FY20

There will be no processing fee and the application will be processed within hours, Oxxy Healthcare said.

USFDA issues warning letter to Lantech Pharma for manufacturing violations at Andhra plant

USFDA issues warning letter to Lantech Pharma for manufacturing violations at Andhra plant

In a warning letter issued to the company's Managing Director V Prakash Reddy, the USFDA said inspectors during March 6-15 this year found significant deviations from standard manufacturing practices at the company's Ranastalam (Srikakulam district) based plant.

Granules India to divest entire stake in Granules OmniChem to JV partner

Granules India to divest entire stake in Granules OmniChem to JV partner

SA Ajinomoto Omnichem NV will take over full control of the contract research and manufacturing services (CRAMS) business, said Granules India.

China's new drug law may open door for Indian generic medicines: Report

China's new drug law may open door for Indian generic medicines: Report

No major Indian pharma company managed to establish itself in China in view of the rigid regulations and the costs involved.

Pharma company accountant held for sharing its data with rival firm

Pharma company accountant held for sharing its data with rival firm

Mahaveer Pharma, a firm based in Chamrajpet, detected that data of all its transactions between April 1 and July 22 had been sent to an unknown person via email.

Lupin's South African arm inks commercial pact with Creso Pharma

Lupin's South African arm inks commercial pact with Creso Pharma

Shares of Lupin Ltd closed at Rs 747.30 per scrip on the BSE, up 1.21 per cent from its previous close.

Chennai startup Eywa enters US pharma market

Chennai startup Eywa enters US pharma market

Eywa Pharma, based in Chennai and with offices in New Jersey, is the new pharma kid on the block that is entering the US market.

Load More...
1

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

BACK TO TOP